Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...